Headlands Technologies’s GSK GSK Stock Holding History

Headlands Technologies’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,730	Closed	-$1.18M	–	1318
2024 Q2	$1.18M	Buy	+30,730	New	+$1.29M	0.13%	148
2023 Q4	–	Sell	-2,338	Closed	-$84.8K	–	1078
2023 Q3	$84.8K	Buy	+2,338	New	+$83K	0.04%	341
2023 Q2	–	Sell	-538	Closed	-$19.1K	–	875
2023 Q1	$19.1K	Buy	+538	New	+$18.8K	0.01%	301

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Headlands Technologies's GSK Position: Q3 2024 in Review

Headlands Technologies sold out of GSK (GSK) in Q3 2024, closing a stake of 30,730 shares — an estimated $1.18M sold.

Headlands Technologies first reported a position in GSK in Q1 2023 and held it in 3 quarters. The position peaked at $1.18M in Q2 2024. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

Headlands Technologies reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
Headlands Technologies sold 30,730 GSK shares in Q3 2024, an estimated $1.18M.
Headlands Technologies first reported a position in GSK in Q1 2023 and held it in 3 quarters.
Headlands Technologies's GSK position peaked at $1.18M in Q2 2024.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Headlands Technologies's 13F filing for Q3 2024, filed 12 Nov 2024.